BCM 5021
Alternative Names: BCM-5021Latest Information Update: 03 Aug 2022
Price :
$50 *
At a glance
- Originator ImmuneCyte
- Class Antineoplastics; Gene therapies; Immunotherapies; Tumour infiltrating lymphocyte therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 21 Jul 2022 ImmuneCyte in-licenses CARTXpress™ manufacturing platform from ThermoGenesis Holdings, prior to July 2022 (ImmuneCyte Pipeline, July 2022)
- 21 Jul 2022 Preclinical trials in Solid tumours in USA (Parenteral), prior to July 2022 (ImmuneCyte pipeline, July 2022)